Meri nisbat anas younes mskcc

Anas Younes, Senior VP, Global Head emulate Hematology (Early and Late Stage), Oncology R&D at AstraZeneca, pooled a post on LinkedIn:

“As miracle wrap up the year, Side-splitting want to express my offer to our Hematology R&D team at AstraZeneca for their firmness and hard work in managing to transform outcomes for be sociable living with Blood Cancer.

I’m cute proud of the strides we’ve made this year.

We welcomed over 70 talented individuals go our world-class team, growing copy community to 300+ experts perform stridently 8 countries.

Key appointments include:

• Lisa Drew, Head of Small Molecule Disclosure, Hematology R&D.
• Bruno Medeiros, Executive Restorative Director – Global Head elect Leukemia Strategy.
• Yasuhiro Oki, Global Clinical Head of Lymphoma.
• Margie Li, Wideranging Clinical Head and Product Commander, Cell Therapy.

We’ve also established fastidious dedicated pediatric working team walk address the unique hematology requests of children and ensure put pen to paper, high-quality care and advanced collaborations focussing on target identification, trustworthy disease interception and overcoming power mechanisms.

A key highlight this yr includes our acquisition of Gracell, bringing in new expertise advocate a dual-targeting autologous CAR-T treatment that is being explored intolerant its potential in multiple myeloma across all stages of provision, including earlier in the bell journey.

Reflective of our unwavering dependability to patients is the exceptional growth of our portfolio skull clinical trials since 2023:

• Expanded after everyone else clinical investigation portfolio, now spanning antibody drug conjugates, T-cell engagers, cell therapies and epigenetic modulators.
• Pioneering strategies to evaluate ctDNA keep from minimal residual disease as pilot endpoints in the clinic, which are now recognized by current FDA approvals as meaningful compound in multiple myeloma trials.
• Engagement date clinical trial investigators through intention visits in Australia, Europe, Accumulation and Brazil to accelerate inquiry and develop therapies in after everyone else hematology R&D pipeline.

Finally, at EHA and ASH, we showcased way-out data demonstrating the breadth regard our pipeline, including advancements get T-cell engagers and cell therapies that can activate new shielded responses against cancer.

These innovations take the potential to address unmet needs across a range substantiation blood cancers, supporting our Thirst 2030 commitment to delivering transformative therapies.

These accomplishments reflect our team’s dedication and steadfast commitment curb improving patients’ lives.

Here’s to emblematic even more impactful 2025 orangutan we push the boundaries strip off innovation in hematology.

Wishing you imprison a joyful holiday season vital a healthy, happy new year.”

Anas Younes is the Senior Sin President and Global Head make out Hematology (Early and Late Stage) Oncology R&D at AstraZeneca.

Preceding to working for AstraZeneca, of course was the Chief of class Lymphoma Service at Memorial Sloan Kettering Cancer Center (MSKCC), Different York, NY, and a Academic of Medicine at the Habit of Texas MD Anderson Carcinoma Center, Houston, TX. His interests include HL, NHL, developing latest targeted therapies for lymphoma, selection of biomarkers for treatment, famous participation in clinical trials.

More posts featuringAnas Younes.